Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
NCT ID: NCT04890548
Last Updated: 2021-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2021-11-23
2022-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients will receive the same sequence of 5 intra-arterial (IA) infusions into the brachial artery, consisting of a baseline saline infusion of approximately 20 minutes, followed by 3 sequential infusions of AZD3427 at ascending doses of approximately 10 minutes (each) and a washout saline infusion of approximately 15 minutes.
For each patient, the study will last at least 51 days and up to 99 days, including:
* A screening period of 1 to 42 days (which will include baseline echocardiography)
* A single-day treatment period during which patients will stay at study site until at least 4 hours after the end of infusions
* A follow-up period of 49 to 56 days after the end of the last infusion including:
A follow-up phone call on Day 2 (within 24 ± 6 hours post-infusion) A follow-up visit on Day 8 (+ 3 days) A follow-up visit on Day 29 (± 2 days) A follow-up visit on Day 50 (+ 7 days)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with HFpEF or HFrEF
Patients will be enrolled in 2 cohorts in parallel: 1 cohort of patients with HFpEF and 1 cohort of patients with HFrEF. Patients will receive a sequence of 5 IA infusions into the brachial artery, consisting of a baseline saline infusion of approximately 20 minutes, followed by 3 sequential infusions of AZD3427 at ascending doses of approximately 10 minutes (each) and a washout saline infusion of approximately 15 minutes.
AZD3427
Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD3427
Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient with known clinical diagnosis of Stage C heart failure New York Heart Association (NYHA) Class I-III and on stable medical therapy for at least 12 weeks prior to screening with no significant dose change or new medications added during that period. Specifically:
1. Patients with a diagnosis of HFrEF, defined as ejection fraction ≤ 40%. OR
2. Patients with a diagnosis of HFpEF, defined as ejection fraction ≥ 50%.
3. Patients with suitable veins and arteries for cannulation or repeated puncture.
4. Patients who are able to lie flat for the duration of IA infusions and related procedures during Visit 2 (approximately 3 hours).
5. Body weight of at least 60 kg and body mass index within the range of 18 to 40 kg/m\^2.
6. Male and/or female of nonchildbearing potential.
7. Capable of giving signed informed consent.
Exclusion Criteria
2. Clinically significant valvular heart disease as judged by the investigator.
3. Congenital heart disease (patients with Patent Foramen Ovale may be included in the study).
4. Clinical diagnosis of heart failure NYHA Class IV.
5. Occurrence in the last 3 months of any of the following:
1. Acute coronary syndrome: myocardial infarction or unstable angina.
2. Percutaneous coronary intervention.
3. Cerebrovascular accident or transient ischaemic attack.
4. Heart failure hospitalisation.
6. History of prior dissections.
7. History or suspicion of cardiac amyloidosis.
8. Patients with conditions where vasodilator therapy may be contraindicated.
9. History of cancer in the last 5 years, except for non-melanoma skin cancer.
10. Any clinically important abnormalities in clinical chemistry, haematology or urinalysis.
11. Any positive result at Screening for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus.
12. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator.
13. Abnormal vital signs, after at least 10-minute supine rest, defined as any of the following at Screening:
1. Systolic blood pressure (BP) \> 160 mmHg.
2. Diastolic BP \> 90 mmHg.
14. Any clinically important abnormalities in rhythm, conduction or morphology of the resting 12-lead electrocardiogram as considered by the investigator.
1. Prolonged QTcF \> 450 ms.
2. Family history of long QT syndrome.
3. Second or third-degree AV block, or sinus node dysfunction with significant sinus pause.
15. History of hypersensitivity to drugs with a similar chemical structure or class to AZD3427.
16. Participants who have previously received AZD3427.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parexel
INDUSTRY
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8330C00002
Identifier Type: -
Identifier Source: org_study_id